Suppression of neovascularization of donor corneas by transduction with equine infectious anemia virus-based lentiviral vectors expressing endostatin and angiostatin

Human Gene Therapy

Volumn 25, Issue 5, 2014, Pages 408-418

  Parker, Maria ^a   Bellec, Jessica ^b   McFarland, Trevor ^a   Scripps, Vicky ^b   Appukuttan, Binoy ^c   Hartzell, Matt ^a   Yeager, Austen ^a   Hady, Thomas ^a   Mitrophanous, Kyriacos A ^b   Stout, Tim ^a   Ellis, Scott ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; LENTIVIRUS VECTOR; GREEN FLUORESCENT PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA TRANSPLANTATION; EQUINE INFECTIOUS ANEMIA VIRUS; EX VIVO GENE TRANSFER; GENE THERAPY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATORY INFILTRATE; NONHUMAN; PRIMATE; RABBIT; RISK FACTOR; ANIMAL; CORNEA; CORNEAL NEOVASCULARIZATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOLOGY; SURGERY; VASCULARIZATION;

ANGIOSTATINS; ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL OPACITY; CORNEAL TRANSPLANTATION; ENDOSTATINS; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; PRIMATES; RABBITS; TRANSDUCTION, GENETIC;

EID: 84901227974     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.079     Document Type: Article

References (55)

1. Anshu, A., Lim, L.S., Htoon, H.M., et al. (2011). Postoperative risk factors influencing corneal graft survival in the Singapore Corneal Transplant Study. Am. J. Ophthalmol. 151, 442-448.e1.
2. Armitage, W.J. (2011). Preservation of human cornea. Transfus. Med. Hemother. 38, 143-147.
3. Azar, D.T. (2006). Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 104, 264-302.
4. Bachmann, B., Taylor, R.S., and Cursiefen, C. (2010). Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 117, 1300-1305.e7.
5. Balaggan, K.S., Binley, K., Esapa, M., et al. (2006). Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J. Gene Med. 8, 275-285.
6. Barcia, R.N., Dana, M.R., and Kazlauskas, A. (2007). Corneal graft rejection is accompanied by apoptosis of the endo-thelium and is prevented by gene therapy with bcl-xL. Am. J. Transplant. 7, 2082-2089.
7. Beutelspacher, S.C., Ardjomand, N., Tan, P.H., et al. (2005). Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. Exp. Eye Res. 80, 787-794.
8. Beutelspacher, S.C., Pillai, R., Watson, M.P., et al. (2006). Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by overexpression. Eur. J. Immunol. 36, 690-700.
9. Binley, K., Widdowson, P., Kelleher, M., et al. (2012). Safety and biodistribution of an equine infectious anemia virusbased gene therapy, RetinoStat, for age-related macular degeneration. Hum. Gene Ther. 23, 980-991.
10. Blezinger, P., Wang, J., Gondo, M., et al. (1999a). Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17, 343-348.
11. Blezinger, P., Yin, G., Xie, L., et al. (1999b). Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models. Angiogenesis 3, 205-210. (Pubitemid 129644149)
12. Boimer, C., Lee, K., Sharpen, L., et al. (2011). Evolving surgical techniques of and indications for corneal transplantation in Ontario from 2000 to 2009. Can. J. Ophthalmol. 46, 360-366.
13. Celik, I., Surucu, O., Dietz, C., et al. (2005). Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65, 11044-11050. (Pubitemid 41713375)
14. Comer, R.M., King, W.J., Ardjomand, N., et al. (2002). Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 43, 1095-1103.
15. Ellis, S., Miskin, J., Binley, K., et al. (2012). LentiVector, a highly effective equine infectious anaemia virus-based lentiviral gene therapy platform for ocular disease. ARVO Meet Abstr. 53, 1912.
16. Gebhardt, B., and Shi, W. (2002). Experimental corneal allograft rejection. Immunol. Res. 25, 1-26.
17. Gong, N., Pleyer, U., Vogt, K., et al. (2007). Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest. Ophthalmol. Vis. Sci. 48, 1043-1052.
18. Hara, H., and Cooper, D.K. (2011). Xenotransplantation - the future of corneal transplantation? Cornea 30, 371-378.
19. Hong, S.Y., Lee, M.H., Kim, K.S., et al. (2004). Adenoassociated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. World J. Gastroenterol. 10, 1191-1197.
20. Jin, X., Bookstein, R., Wills, K., et al. (2001). Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 8, 982-989. (Pubitemid 33140317)
21. Kampik, D., Ali, R.R., and Larkin, D.F. (2011). Experimental gene transfer to the corneal endothelium. Exp. Eye Res. 95, 54-59.
22. Kim, J.H., Kim, J.C., Shin, S.H., et al. (1999). The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp. Mol. Med. 31, 203-209.
23. Klebe, S., Sykes, P.J., Coster, D.J., et al. (2001). Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 71, 1214-1220. (Pubitemid 32507137)
24. Klebe, S., Coster, D.J., Sykes, P.J., et al. (2005). Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J. Immunol. 175, 2219-2226. (Pubitemid 41113828)
25. Konig Merediz, S.A., Zhang, E.P., Wittig, B., et al. (2000). Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epitheliumin mice after orthotopic corneal allograft transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 238, 701-707.
26. Lai, L.J., Xiao, X., and Wu, J.H. (2007). Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J. Biomed. Sci. 14, 313-322.
27. Ma, D.H., Chen, J.K., Zhang, F., et al. (2006). Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog. Retin. Eye Res. 25, 563-590.
28. Murthy, R.C., Mcfarland, T.J., Yoken, J., et al. (2003). Corneal transduction to inhibit angiogenesis and graft failure. Invest. Ophthalmol. Vis. Sci. 44, 1837-1842.
29. Nakao, S., Hafezi-Moghadam, A., and Ishibbashi, T. (2012). Lymphatics and lymphangiogenesis in the eye. J. Ophthalmol. 2012, 783163.
30. Noro, T., Miyake, K., Suzuki-Miyake, N., et al. (2004). Adenoassociated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res. 64, 7486-7490. (Pubitemid 39372092)
31. Ohlmann, A.V., Ohlmann, A., Welge-Lussen, U., et al. (2005). Localization of collagen XVIII and endostatin in the human eye. Curr. Eye Res. 30, 27-34.
32. Panda, A., Vanathi, M., Kumar, A., et al. (2007). Corneal graft rejection. Surv. Ophthalmol. 52, 375-396.
33. Patel, S.V. (2011). Graft survival after penetrating keratoplasty. Am. J. Ophthalmol. 151, 397-398.
34. Perera, C., Jhanji, V., and Vajpayee, R.B. (2011). Factors influencing outcomes of the treatment of allograft corneal rejection. Am. J. Ophthalmol. 152, 358-363.e2.
35. Pleyer, U., Bertelmann, E., Rieck, P., et al. (2000). Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch. Clin. Exp. Ophthalmol. 238, 531-536.
36. Ponnazhagan, S., Mahendra, G., Kumar, S., et al. (2004). Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 64, 1781-1787. (Pubitemid 38428702)
37. Rahman, I., Huang, M.C., Carley, F., et al. (2010). The influence of donor and recipient factors in allograft rejection of the human cornea. Eye (Lond.) 24, 334-339.
38. Rocher, N., Behar-Cohen, F., Pournaras, J.A., et al. (2011). Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. Mol. Vis. 17, 104-112.
39. Saban, D., Dastjerdi, M., and Dana, R. (2010). Chapter 8: corneal graft rejection. In Ocular Disease: Mechanisms and Management. L.A. Levin and D.M. Albert, eds. (Saunders, New York, NY), pp. 56-63.
40. Sauter, B., Martinet, O., Zhang, W., et al. (2000). Adenovirus- mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 97, 4802-4807.
41. Shao, X.J., and Chi, X.Y. (2005). Influence of angiostatin and thalidomide on lymphangiogenesis. Lymphology 38, 146-155. (Pubitemid 41609631)
42. Shi, W., Teschendorf, C., Muzyczka, N., et al. (2002). Adenoassociated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 9, 513-521. (Pubitemid 34569034)
43. Shi, W., Teschendorf, C., Muzyczka, N., et al. (2003). Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol. 66, 1-9.
44. Shin, S.H., Kim, J.C., Chang, S.I., et al. (2000). Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea 19, 212-217. (Pubitemid 30140826)
45. Subramanian, I.V., Ghebre, R., and Ramakrishnan, S. (2005). Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther. 12, 30-38. (Pubitemid 40090042)
46. Tjin Tham Sjin, R.M., Naspinski, J., Birsner, A.E., et al. (2006). Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther. 13, 619-627.
47. Venkataraman, B. (2008). Countries make push to increase eye donors. The New York Times, July 15, 2008.
48. Wang, X., Appukuttan, B., Ott, S., et al. (2000). Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Ther. 7, 196-200. (Pubitemid 30113767)
49. Wen, X.Y., Bai, Y., and Stewart, A.K. (2001). Adenovirusmediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum. Gene Ther. 12, 347-358.
50. Williams, K., and Coster, J. (1993). Clinical and experimental aspects of corneal transplantation reviews. Transplant. Rev. 7, 44-64.
51. Williams, K.A., Lowe, M., Bartlett, C., et al. (2008). Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 86, 1720- 1724.
52. Wong, L.-F., Yip, P., Battaglia, A., et al. (2006). Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat. Neuro. 9, 243-250.
53. Zhang, E.P., Franke, J., Schroff, M., et al. (2003). Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefes Arch. Clin. Exp. Ophthalmol. 241, 921-926.
54. Zhang, X., Xu, J., Lawler, J., et al. (2007). Adeno-associated virusmediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin. Cancer Res. 13, 3968-3976.
55. Zhuo, W., Chen, Y., Song, X., et al. (2011). Endostatin specifically targets both tumor blood vessels and lymphatic vessels. Front. Med. 5, 336-340.